Predictors of immunotherapy-induced immune-related adverse events

about

Predictors of immunotherapy-induced immune-related adverse events

Item

http://www.wikidata.org/entity/Q59135410

description

im November 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 31 October 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в листопаді 2018

@uk

name

Predictors of immunotherapy-induced immune-related adverse events

@en

Predictors of immunotherapy-induced immune-related adverse events

@nl

type

Item

label

Predictors of immunotherapy-induced immune-related adverse events

@en

Predictors of immunotherapy-induced immune-related adverse events

@nl

prefLabel

Predictors of immunotherapy-induced immune-related adverse events

@en

Predictors of immunotherapy-induced immune-related adverse events

@nl

P1476

Predictors of immunotherapy-induced immune-related adverse events

@en

P2093

A Kartolo

http://www.w3.org/2001/XMLSchema#string

J M Lakoff

http://www.w3.org/2001/XMLSchema#string

J Sattar

http://www.w3.org/2001/XMLSchema#string

T Baetz

http://www.w3.org/2001/XMLSchema#string

V Sahai

http://www.w3.org/2001/XMLSchema#string

P2860

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

Mechanisms of sex disparities in influenza pathogenesis

Toxicities of Immunotherapy for the Practitioner

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial.

Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.

P304

e403-e410

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3747/CO.25.4047

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30464691

http://www.w3.org/2001/XMLSchema#string

P921

immunotherapy

P932

6209550

http://www.w3.org/2001/XMLSchema#string